ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascular Research

Executive Summary: ML-7 hydrochloride (SKU A3626, APExBIO) is a potent inhibitor of myosin light chain kinase (MLCK) with a Ki of 300 nM, enabling precise regulation of myosin light chain (MLC) phosphorylation in muscle contraction and cell motility studies (APExBIO product page). In vitro and in vivo, ML-7 improves contractility in ischemia/reperfusion (I/R) cardiac models and modulates tight junction proteins relevant to vascular endothelial function (Wei et al., 2019). The compound is highly soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL with gentle warming), but insoluble in ethanol. ML-7 hydrochloride is supplied at ≥98% purity for research use only. Its validated selectivity and robust performance make it a reference standard for dissecting the MLCK pathway in cardiovascular and atherosclerosis research (See also).

Biological Rationale

Myosin light chain kinase (MLCK) is an essential enzyme responsible for the phosphorylation of myosin light chains (MLC), a critical step in actin-myosin interactions and muscle contraction (Wei et al., 2019). MLCK-mediated signaling regulates smooth muscle tone, cardiac function, and cellular motility in diverse physiological and pathophysiological contexts. Aberrant MLCK activity contributes to cardiovascular diseases, including ischemia/reperfusion injury, atherosclerosis, and vascular endothelial dysfunction. Targeted inhibition of MLCK enables researchers to dissect the downstream effects of MLC phosphorylation, including altered contractility, cytoskeletal dynamics, and barrier integrity. ML-7 hydrochloride, as a highly selective MLCK inhibitor, provides a well-characterized pharmacological tool for these investigations (Unlocking the Power of MLCK Inhibition—this article adds updated evidence from recent in vivo models).

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) selectively inhibits MLCK with a Ki of 300 nM under standard assay conditions (25°C, Tris buffer, pH 7.2). The compound competes with ATP at the catalytic site, thereby blocking MLCK-mediated phosphorylation of the regulatory MLC on serine-19. This inhibition prevents the conformational activation of myosin, disrupting actin-myosin cross-bridge cycling and reducing contractile force generation in smooth and cardiac muscle (APExBIO). ML-7 also modulates cytoskeletal organization, impacting cell shape, migration, and barrier function through downstream MLC-dependent processes. Notably, ML-7 shows minimal off-target activity at concentrations up to 10 μM in most cell-based assays, distinguishing it from broader kinase inhibitors (Blebbistatin.com review—the present article outlines ML-7's unique selectivity profile).

Evidence & Benchmarks

• ML-7 inhibits MLCK activity with a Ki of 300 nM (25°C, Tris-HCl, pH 7.2), demonstrating high specificity compared to structurally related kinases (APExBIO).
• In neonatal rat cardiomyocytes, ML-7 (10 μM, 1 hour) blocks recombinant human neuregulin-1 (rhNRG-1)-induced restoration of sarcomeric organization, confirming MLCK pathway involvement in cardiac remodeling (Wei et al., 2019).
• In vivo, ML-7 administered intravenously (1 mg/kg) before ischemia and during reperfusion improves left ventricular contractility and modulates proteins linked to energy metabolism and oxidative stress in I/R-injured rat hearts (Wei et al., 2019).
• In rabbit models of atherosclerosis, ML-7 (5 mg/kg/day, 4 weeks) ameliorates vascular endothelial dysfunction by regulating tight junction proteins ZO1 and occludin, via inhibition of MLCK and suppression of MLC phosphorylation (Wei et al., 2019).
• ML-7 exhibits robust solubility in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL with gentle warming/ultrasonic treatment) but is insoluble in ethanol (APExBIO).
• ML-7 solutions are stable for short-term use when stored at -20°C and protected from light (APExBIO).

Applications, Limits & Misconceptions

ML-7 hydrochloride is extensively applied in research models investigating:

• Cardiovascular disease mechanisms, especially ischemia/reperfusion injury and contractile dysfunction.
• Vascular endothelial barrier regulation via tight junction proteins (e.g., ZO1, occludin).
• Atherosclerosis progression and intervention in animal models (Scenario-driven guidance—the current article extends the evidence base with new quantitative data).
• Cell migration, cytoskeletal organization, and epithelial permeability assays.
• Dissection of MLCK/MLC signaling pathways in cellular and tissue models.

Common Pitfalls or Misconceptions

• ML-7 is not suitable for in vivo diagnostic or therapeutic use; it is intended for research applications only (APExBIO).
• ML-7 does not inhibit all myosin isoforms equally; its selectivity is highest for smooth and cardiac MLCK, not skeletal muscle MLCK or unrelated kinases (Blebbistatin.com).
• Solubility in ethanol is poor; use DMSO or water (with gentle warming and ultrasound) for preparation.
• Long-term solution storage (>1 week) may lead to degradation; fresh aliquots are recommended for reproducibility.
• ML-7 may not fully recapitulate genetic MLCK knockout effects, especially in complex, multi-kinase cellular environments.

Workflow Integration & Parameters

For optimal results, prepare ML-7 hydrochloride stock solutions at 10–20 mM in DMSO and dilute to working concentrations (0.1–10 μM) in physiological buffers immediately before use. Water-based stocks (≥8.82 mg/mL) may be used with gentle warming and ultrasonic agitation. Filter sterilization is recommended for cell culture applications. Store both powder and solutions at -20°C, protected from light, and avoid repeated freeze-thaw cycles for maximal stability. For cardiovascular disease models, administer ML-7 intravenously or intraperitoneally according to protocol-specific dosing (typically 1–5 mg/kg for rodents). Monitor experimental endpoints such as MLC phosphorylation (immunoblot), contractility (Langendorff or echocardiography), and tight junction protein expression. For a comprehensive workflow and troubleshooting guidance, see Practical Solutions for Researchers—the present article updates dosing and stability recommendations.

Conclusion & Outlook

ML-7 hydrochloride (SKU A3626, APExBIO) is a reference-grade, selective MLCK inhibitor with validated performance in cardiovascular, atherosclerosis, and endothelial dysfunction models. Its atomic, testable properties—high potency (Ki 300 nM), selectivity, and superior solubility—support reproducible dissection of the MLCK/MLC pathway in vitro and in vivo. While not intended for clinical use, ML-7 remains an indispensable tool for mechanistic and translational research into contractility, cytoskeletal regulation, and vascular integrity. Future advances may leverage ML-7's precision to further understand disease mechanisms and benchmark new therapeutic candidates. For detailed product information and ordering, visit the ML-7 hydrochloride product page.